Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

cabazitaxel × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 68 Tumor-Agnostic 8 Breast 6 Gastrointestinal 4 Thoracic 3 Head & Neck 3 CNS 3 Other solid neoplasm 2 Gynecologic 2 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Endocrine 1 Classical hematology 1

Conditions

Interventions

Cyclophosphamide 189 Radiotherapy 188 Doxorubicin 181 Temozolomide 162 Ifosfamide 104 Filgrastim 97 Imatinib Mesylate 92 Etoposide 88 Vincristine 80 Gemcitabine 75 Bevacizumab 71 Irinotecan 69 Magnetic Resonance Spectroscopy 66 pembrolizumab 60 Radiation 60 Carboplatin 55 Methotrexate 53 pazopanib 52 fludarabine phosphate 50 Cisplatin 49 Trabectedin 48 Specimen Handling 48 Nivolumab 47 Peripheral Blood Stem Cell Transplantation 46 Biopsy 45 Surgical Procedures, Operative 43 Docetaxel 43 Busulfan 43 Melphalan 42 Sunitinib 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01913652 2021-09-14

Ph II Cabazitaxel DD Liposarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡